Announcement on Obtaining Drug Registration Certificate for Tofacitinib Citrate Sustained-release Tablets by Wholly-owned Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(603538)"Ningbo Menovo Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Tofacitinib Citrate Sustained-release Tablets by Wholly-owned Subsidiary
Filed with SSE · Stock code 603538 · · 2 pages · Chinese
Summary by 6ix AI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary has received a drug registration certificate for Tofacitinib Citrate Sustained-release Tablets from the National Medical Products Administration. This approval allows the company to produce and sell the drug in the domestic market, enhancing its product competitiveness. The filing also highlights potential risks related to market demand and competition that could affect future sales of the drug.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Release
Ningbo Menovo Pharmaceutical Co., Ltd. on 6ix
Story so far
- Announcement on Change of Sponsor and Sponsor Representative
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Ningbo Menovo Pharmaceutical: Announcement on the Dilution of Immediate Returns, Measures to Mitigate Such Dilution and the Undertakings by Relevant Parties in Relation to the 2026 Private Placement of A-Shares (Revised Draft)
Earlier from Ningbo Menovo Pharmaceutical
- Announcement on Change of Sponsor and Sponsor Representative
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Ningbo Menovo Pharmaceutical: Announcement on the Dilution of Immediate Returns, Measures to Mitigate Such Dilution and the Undertakings by Relevant Parties in Relation to the 2026 Private Placement of A-Shares (Revised Draft)
- Announcement on Completion of the Industrial and Commercial Registration Change and Issuance of a New Business License
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
Later from Ningbo Menovo Pharmaceutical
All Ningbo Menovo Pharmaceutical news releasesFollow Ningbo Menovo Pharmaceutical into a list and get an email when it puts out news.
Follow Ningbo Menovo Pharmaceutical